Results 261 to 270 of about 71,029 (345)

Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection. [PDF]

ADMET DMPK
Nur Y, Zein MIH, Irkham I, Gaffar S, Subroto T, Hartati YW.   +5 more
europepmc   +1 more source

Non-Traumatic Spontaneous Splenic Rupture: A Rare Initial Presentation of Chronic Myeloid Leukaemia

, 2017
Sathish Kumar A
openalex   +1 more source

Characterizing and assessing vision‐related quality of life among patients discontinued treatment for neovascular age‐related macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose This study characterized and assessed vision‐related quality of life (VRQoL) in patients with neovascular age‐related macular degeneration (nAMD) who discontinued treatment with intravitreal anti‐vascular endothelial growth factor (anti‐VEGF), comparing them to those undergoing treatment.
Noreddin Shekho, Anna Stage Vergmann, Frederik Nørregaard Pedersen, Lonny Stokholm, Benjamin Sommer Thinggaard   +4 more
wiley   +1 more source

Long-term endocrine outcomes and quality of life in paediatric and young chronic myeloid leukaemia patients on tyrosine kinase inhibitor therapy: a prospective study from India. [PDF]

Front Oncol
Mohan R, Nagpal C, Upadhya S, Kumar A, Khadgawat R, Bakhshi S, Pushpam D.   +6 more
europepmc   +1 more source

Outcome prediction of chronic myeloid leukaemia (CML) in children [PDF]

Wing Yan Leung, Daniel KL Cheuk, W.T. Frankie, Alex Wing Kwan Leung, Ka Ho Chiu, Karin Kar Huen Ho, Chi Kong Li, Godfrey Chi Fung Chan   +7 more
openalex   +1 more source

Treatment of lung adenocarcinoma with chemotherapy helps mitigate chronic myeloid leukaemia progression: A case report. [PDF]

Oncol Lett
Nagasue K, Kida R, Shigaki R, Nitanai K, Yagita A, Yanada H, Umekage Y, Mori C, Minami Y, Funayama T, Yamamoto M, Tanino M, Yoshida R, Sasaki T.   +13 more
europepmc   +1 more source

Characterisation of normal and leukaemic stem cells in chronic myeloid leukaemia / Ian D. Lewis.

, 1998
Ian D. Lewis
openalex   +1 more source

Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA‐VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Induction chemotherapy in fit de novo acute myeloid leukaemia (AML) patients has historically combined an anthracycline with standard‐dose cytarabine (‘7 + 3’) despite complete response (CR) rates of 50%–70%. In May 2023, our institution adopted the utilization of cladribine, cytarabine, idarubicin and venetoclax (CLIA‐VEN) for intensive ...
Benjamin J. Lee, Shawn P. Griffin, Jean Doh, Anthony Quach, Yujiao Sun, Piyatida Chumnumsiriwath, Stefan O. Ciurea, Jorge Ramos‐Perez, Polina Bellman, Deepa Jeyakumar, Piyanuch Kongtim, Kiran Naqvi   +11 more
wiley   +1 more source

Chronic myeloid leukaemia

, 2012
openaire   +1 more source

Comorbidities and mutations including single‐ and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia—A population‐based study

British Journal of Haematology, EarlyView.
In a population‐based cohort of 149 chronic myelomonocytic leukaemia (CMML) patients, multihit TET2 mutation was associated with older age, lower LDH and less leucocytosis. We found no association with autoimmune disease or thrombosis. Patients with multihit TET2 mutation had a significantly longer overall survival than the patients without or with one
Matilda Kjellander Kynning, Ebba Westerberg, Linda Forsell, Maria Creignou, Daniel Moreno Berggren, Bianca Tesi, Elsa Bernard, Elli Papaemmanuil, Yasuhito Nannya, Lucia Cavelier Franco, Davide Valentini, Eva Hellström Lindberg, Seishi Ogawa, Elisabeth Ejerblad, Johanna Ungerstedt   +14 more
wiley   +1 more source